← 홈

프로그램 비교

검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 13일

현재 선택: 1

프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.

API CSV18행 · 1개 프로그램

표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.

항목
AntibodyPhase 1
AZD1390 (AZD1390)
University of Leeds·Non Small Cell Lung Cancer
9 trials
Overview
Program
AZD1390
Overview
Company
University of Leeds
Overview
Modality
ANTIBODY
Overview
Target
Non Small Cell Lung Cancer
Overview
Indication
Non Small Cell Lung Cancer
Overview
Phase
PHASE_1
Overview
Status
RECRUITING
MoA
Mechanism
targeting TAT-activated and survival-promoting signaling pathway
MoA
Biomarker
biomarkers and therapeutic targets informing precision medicine strategies for PBT are mostly missing
PK/PD
Species
Mouse
PK/PD
Animal (cat.)
Mouse, In vitro
PK/PD
Experiment
Pk
Toxicology
Species
Mouse
Toxicology
Animal (cat.)
Mouse, In vitro
Toxicology
Major finding
Inhibition of ATM reverses radioiodine resistance in differentiated thyroid cancer via genotoxic stress amplification.. Radioiodine (RAI) resistance is a major barrier in the treatment of differentiated thyroid cancer (DTC), especially in tumors that retain iodine uptake but fail to respond. The role of DNA repair mechanisms, particularly ataxia-telangiectasia mutated (ATM) kinase, in this resista…
Clinical
Data Tier / Score
A · 20
Clinical
Program phase
PHASE_1
Clinical
Clinical sync
2026년 7월 13일 (1일 전)